Comparison of Lanreotide and Octreotide LAR Use and Outcomes for Gastrointestinal Neuroendocrine Tumors in British Columbia, Canada - Research Article

Sep 22, 2026

Upload by Levi

Long-acting somatostatin analogs octreotide LAR (OCT) and lanreotide (LAN) improve progression-free survival in gastrointestinal neuroendocrine tumors, yet no head-to-head comparison exists. A population-based cohort from British Columbia, Canada, retrospectively evaluated 321 patients receiving either LAN or OCT. LAN use was more frequent in higher-grade tumors and was associated with longer progression-free survival and overall survival, with similar dose escalation and less short-acting rescue octreotide use, though retrospective design limits causal inference.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages9

Reading Time23 min

AccessFree to download

Abstract

Introduction

Methods

Results

Conclusion

Plain Language Summary

Keywords

Received, revised, accepted

Advances in the Treatment and Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) - Research Article | Comparison of Lanreotide and Octreotide LAR Use and Outcomes for Gastrointestinal Neuroendocrine Tumors in British Columbia, Canada | Cancer Control Volume 33: 1-9 © The Author(s) 2026 Article reuse guidelines:
[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/10732748261417423](DOI: 10.1177/10732748261417423)
[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)

| | --- | --- | | Ashley Paul, MD 1, Shehara Mendis, MBBS 1, Michael Diaz-Stewart, BSc2 􀀁, Justin Jao, BSc1,
Melina Boutin, MD 1, Maria Safro, MD 1, Marie-Hlène Denault, MD 1, Caroline Speers, BA, CHIM 1, Heather Stuart, MD3, Sharlene Gill, MD 1, Daniel J. Renouf, MD 1, David F. Schaeffer, MD3, David Farnell, MD3, and Jonathan M. Loree, MD 1
Abstract
Introduction: The long-acting somatostatin analogues (LA-SSAs) octreotide LAR (OCT) and lanreotide (LAN) improve progression-free survival (PFS) in gastrointestinal neuroendocrine tumors (NETs), however, no head-to-head comparison exists. We compared treatment patterns and efﬁcacy in a small bowel and pancreatic NET population-based cohort from British Columbia, Canada.
Methods: We identiﬁed 321 patients receiving either LAN or OCT for retrospective chart review. These somatostatin analogs were evaluated for impact on progression-free and overall survival.
Results: Age, sex, ECOG, and primary site did not differ by treatment, however, LAN was more commonly used in higher grade tumors (P = 0.019). PFS was longer for patients receiving LAN than OCT (Hazard Ratio (HR) 0.60, 95% CI 0.40-0.89, P = 0.011). Similarly, overall survival (OS) was longer for patients receiving LAN than OCT (HR 0.45, 95% CI 0.28-0.73, P = 0.016). Sensitivity analysis among patients diagnosed after both agents were reimbursed showed similar results for PFS (HR 0.50, 95% CI 0.28-0.90, P = 0.018). There was similar dose escalation with LAN vs OCT (OR: 0.80, CI 0.38-1.77, P = 0.70), with 29.4% of patients in the LAN group requiring LA-SSA dose escalation compared to34.3%in the OCT group. There was numerically less short acting octreotide use in the LAN group (P = 0.087), with none of these patients requiring short acting octreotide, compared to 8.7% of the OCT group. Conclusion: LAN was associated with longer time to cancer progression, as well as less use of short acting rescue octreotide in our population-based cohort. However, given the retrospective design and reimbursement-era differences, these ﬁndings should be interpreted cautiously and warrant conﬁrmation in prospective or head-to-head studies.
Plain Language Summary
Comparing the outcomes from Lanreotide and Octreotide LAR in a subset of digestive system cancers using a British Columbia Cohort: This study looked at how two medications—Octreotide LAR and Lanreotide—are used to treat people with neuroendocrine tumors(NETs)in the small bowel and pancreas in British Columbia, Canada. These drugs helpslow the growth oftumors, but no direct comparisons have been made between them in clinical trials. Using healthcare records, this study compared how often each | | | 1 BC Cancer, Vancouver, BC, Canada
2University of British Columbia, Vancouver, BC, Canada 3Vancouver General Hospital, Vancouver, BC, Canada
Corresponding Author:
Jonathan M. Loree, MD, BC Cancer, 750 West Broadway, Vancouver, BC V5Z1H5, Canada. Email: Jonathan.Loree@bccancer.bc.ca | | Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as speciﬁed on the SA

FAQs

How were lanreotide and octreotide LAR compared in this study?

The study used a retrospective chart review of 321 patients in British Columbia, Canada, who received either LAN or OCT. Outcomes included progression-free and overall survival.

What did the study find about progression-free survival?

Patients receiving LAN had longer progression-free survival than those receiving OCT (HR 0.60, 95% CI 0.40-0.89, P = 0.011). Sensitivity analysis showed similar results for PFS.

Did the study observe differences in dose escalation or short-acting rescue use?

Dose escalation was similar between LAN and OCT, but fewer LAN patients required short-acting rescue octreotide. The study also reports that most medication switches were due to side effects.

Sep 22, 2026

Upload by Levi